Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis

Register of interests (PDF 175 KB)

TA398 final scope (PDF 97 KB)

TA398 final stakeholder list (PDF 38 KB)

TA398 ACD (PDF 571 KB)

TA398 ACD committee papers (PDF 6.87 MB)

TA398 FAD (PDF 518 KB)

TA398 FAD committee papers (PDF 2.37 MB)

TA398 scoping EIA form (PDF 64 KB)

TA398 final guidance EIA form (PDF 178 KB)

Equality and health inequalities assessment (downloadable version) (PDF 150 KB)

Final draft guidance

Final draft guidance (PDF 347 KB)

Committee papers (PDF 6.05 MB)

Public committee slides (PDF 734 KB)

Updated scope (PDF 214 KB)

Updated consultation comments table (PDF 304 KB)

Equality impact assessment (downloadable version) (PDF 150 KB)

Draft guidance

Committee papers (PDF 17.7 MB)

Public committee slides (PDF 1.98 MB)

Draft guidance (online commenting)

Draft guidance (PDF version) (PDF 391 KB)

Draft guidance (PDF version) Equality Impact Assessment (PDF 154 KB)

Committee meeting: 2

Supporting documentation Update for stakeholders (PDF 124 KB)

Supporting documentation Update for stakeholders (PDF 144 KB)

Assessment report (PDF 6.9 MB)

Final stakeholder list (PDF 191 KB)

Equality impact assessment (Scoping) (PDF 137 KB)

Final scope (PDF 211 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 442 KB)

Final protocol (PDF 1.27 MB)

Statement from NICE and the SMC/HIS (MSWord 22 KB)

Draft scope post referral (PDF 213 KB)

Draft matrix of consultees and commentators post referral (PDF 189 KB)